Transplanting Induced Pluripotent Stem Cell-derived Neural Stem/Progenitor cells for Treating Spinal Cord Injury
Vol. 7 No. 2 (2023), Review
Vol. 7 No. 2 (2023)

Transplanting Induced Pluripotent Stem Cell-derived Neural Stem/Progenitor cells for Treating Spinal Cord Injury

Review
Published 2023-07-19
  • Hao Song
  • Chuanfei Wei
  • Xianjie Lu
  • Zhongyuan Chen
  • Hui Zhao
  • Fabin Han
Hao Song
Chuanfei Wei
Xianjie Lu
Zhongyuan Chen
Hui Zhao
Fabin Han
PDF

Keywords

iPS cells; spinal cord injury; transplantation; neural differentiation

How to Cite

Song, H., Wei, C., Lu, X., Chen, Z., Zhao, H., & Han, F. (2023). Transplanting Induced Pluripotent Stem Cell-derived Neural Stem/Progenitor cells for Treating Spinal Cord Injury. American Journal of Translational Medicine, 7(2), 86–91. Retrieved from https://journals3.publicknowledgeproject.org/index.php/ajtm/article/view/2843
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Spinal cord injury (SCI) is mainly caused by external factors, both direct andindirect, such as high-altitude falls, traffic accidents, sports injuries, etc. SCI results in a high disability rate and a high mortality rate, and is hardly treated. In recent years, stem cells have been used to treat various diseases. Stem cell transplantation can repair and improve the nerves damaged in spinal cord injury. With the development of embryonic stem cells and induced pluripotent stem cells (iPSCs), numerous studies have confirmed that transplanting iPSC-derived neural stem/progenitor cells (iPSC-NSC/NPCs) is the most promising approach for treating spinal cord injury. This review briefly introduces the advantages of therapies based on iPSC-derived neural stem/progenitor cells (iPSC-NSC/NPCs) and related issues of iPS cell-based transplantation therapy for SCI.

Am J Transl Med 2023. 7(2): 86-91

PDF